Medtronic

Current directors and officers who also hold a role at another S&P 500 company.

• Craig ArnoldHONA · DirectorHON · DirectorKKR · DirectorPG · Director
• Elizabeth G. NabelMRNA · Director
• Geoffrey MarthaNEE · Director
• Lidia FonsecaPFE · Officer
• Scott C. DonnellyTXT · Chair

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 19, 2026

   On October 15, 2026, the Board of Directors (the "Board") of Medtronic plc (the “Company”) approved the appointment of Michael Marinaro, Executive Vice President and President, Medical Surgical Portfolio, Americas, and Global Commercial Operations to the role of President, Medtronic, effective October 14, 2026. In this expanded role, Mr. Marinaro will continue with his current responsibilities, in addition to exercising oversight responsibility for the Company’s Greater China operations, which will continue to be managed locally by Alex Gu, Senior Vice President and President, Greater China. Mr. Marinaro will continue to report to Geoffrey S. Martha, who will continue to serve as the Company’s Chairman of the Board of Directors and Chief Executive Officer. In connection with Mr.

   Read the 8-K filing
2. May 18, 2026

   On May 18, 2026, Medtronic plc (“Medtronic” or the “Company”) announced that Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio, and that Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026. Mr. Wall will remain an employee of the Company until September 1, 2026, to assist with the transition. Mr. Wall is entitled to and will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers as described in Medtronic’s 2025 Proxy Statement filed with the Securities and Exchange Commission on August 25, 2025.

   Read the 8-K filing
3. Nov 3, 2025

   On November 1, 2025, Gregory L. Smith, Executive Vice President, Enterprise Operations of Medtronic plc (the Company), notified the Company of his decision to retire from the Company, effective December 2, 2025, and to join a private equity-held organization. As of that date, Mr. Smith will be eligible for retirement treatment of his outstanding equity compensation as disclosed in the Company’s annual definitive proxy statement filed on August 25, 2025. Retirement treatment of equity includes acceleration of unvested stock options and continued vesting of restricted stock units (RSUs) and performance stock units (PSUs) consistent with the forms of those equity award agreements publicly filed with the U.S. Securities and Exchange Commission.

   Read the 8-K filing
4. Aug 19, 2025

   On August 18, 2025, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 11 to 13 and appointed John Groetelaars and William Jellison as new directors of the Company, in each case, effective as of August 19, 2025. Mr. Jellison has been appointed to serve on the newly created Growth committee of the Board and the newly created Operations committee of the Board, and Mr. Groetelaars has been appointed to serve on the newly created Growth committee of the Board. In connection with the appointment of Messrs. Groetelaars and Jellison to the Board, pursuant to the Company’s non-employee director compensation policy, Messrs.

   Read the 8-K filing
5. Jun 23, 2025

   On June 18, 2025, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director of the Company, in each case effective as of June 18, 2025. Dr. Lee has been appointed to serve on the Science and Technology Committee and the Compensation and Talent Committee of the Board. In connection with his appointment to the Board, pursuant to the Company’s non-employee director compensation policy, Dr. Lee will be eligible to receive an annual cash retainer and a director equity grant, in each case as described under “Corporate Governance—Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on August 9, 2024. There were no arrangements or understandings between Dr.

   Read the 8-K filing
6. May 21, 2025

   As referenced in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K, the Company announced that Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio and Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio, effective May 21, 2025. Mr. Salmon will remain an employee of the Company until September 2, 2025. Mr. Salmon is entitled to and will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers described in Medtronic’s 2024 Proxy Statement filed with the Securities and Exchange Commission on August 9, 2024.

   Read the 8-K filing
7. Mar 17, 2025

   Transition of Principal Accounting Officer On March 12, 2025, Jennifer M. Kirk, the Global Controller and Principal Accounting Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective May 2, 2025, to become the chief executive officer of Exubrion Therapeutics, a privately held company. Ms. Kirk’s resignation did not result from any disagreement relating to the Company’s operations, policies or practices. The Company has appointed Denise L. Blomquist, currently the Company’s Assistant Global Controller, to succeed Ms. Kirk as the Company’s Global Controller and Principal Accounting Officer, effective March 17, 2025. As noted above, Ms. Kirk will remain at the Company through May 2, 2025 to support a smooth transition. Ms.

   Read the 8-K filing
8. Jan 21, 2025

   Appointment of Thierry Pieton as Chief Financial Officer of Medtronic plc On January 21, 2025, Medtronic plc (Company) announced the appointment of Thierry Pieton, age 54, as the Company’s Executive Vice President and Chief Financial Officer (CFO), effective as of March 3, 2025 (Effective Date). Thierry Pieton is a global finance executive with experience across many of the world's most operationally-focused companies and industries, including almost 16 years within the General Electric (GE) group of companies. Mr. Pieton began his career as an auditor at PricewaterhouseCoopers (PwC) before moving into finance business partner roles, first at GE Healthcare and then at GE. From GE, Mr. Pieton joined Nissan Motor Company in 2014 as its Senior Vice President, Administration & Finance for Europe. In 2016, Mr. Pieton moved to Renault, S.

   Read the 8-K filing
9. Aug 16, 2024

   of the Current Report on Form 8-K filed by Medtronic plc (the “Company”) with the Securities and Exchange Commission on June 26, 2024 (the “Original Report”). The Original Report confirmed that Gary Corona had been appointed as interim Chief Financial Officer of the Company effective as of August 3, 2024. On August 15, 2024 the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) approved certain modifications to Mr. Corona’s compensation arrangements in connection with his appointment as interim Chief Financial Officer. The Company hereby amends the Original Report to include information on Mr. Corona’s compensation. Other than providing the additional information in

   Read the 8-K filing
10. Jun 26, 2024

    On June 21, 2024, Karen L. Parkhill, Executive Vice President and Chief Financial Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective August 2, 2024. On June 26, 2024, the Company announced that Gary Corona, currently Senior Vice President, Global Financial Planning and Analysis, has been appointed to serve as interim Chief Financial Officer (Interim CFO) of the Company, effective upon Ms. Parkhill’s departure. Mr. Corona, age 50, has served as Senior Vice President, Global Financial Planning and Analysis since joining the Company in January 2023. Prior to his role at Medtronic, Mr. Corona served as Vice President, Corporate Finance at General Mills, Inc., where he held finance roles of increasing responsibility during his 26 year tenure. There is no arrangement or understanding between Mr.

    Read the 8-K filing
11. Jun 4, 2024

    On June 1, 2024, Rob ten Hoedt, Executive Vice President and President, Global Regions of Medtronic plc (Company), notified the Company of his decision to retire from the Company, effective as of June 28, 2024.

    Read the 8-K filing
12. Feb 20, 2024

    As referenced in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K, the Company announced on February 20, 2024 its decision to wind down and exit the ventilator business and combine the remaining businesses within its Patient Monitoring and Respiratory Interventions operating units into a single operating unit. These operational changes will result in the elimination of the position of Executive Vice President and President of Medtronic’s Medical Surgical Portfolio, currently held by Robert J. White. Mr. White will leave the Company effective April 26, 2024, and because Mr. White’s separation from Medtronic constitutes a termination without cause, Mr.

    Read the 8-K filing
13. Oct 23, 2023

    Approval of a Medtronic plc 2024 Employee Stock Purchase Plan; Termination of Medtronic plc 2014 Amended and Restated Employees Stock Purchase Plan On June 22, 2023, the Board of Directors (the “ Board ”) of Medtronic plc, a public limited company organized under the laws of Ireland (the “ Company ”) adopted the Medtronic plc 2024 Employee Stock Purchase Plan (the “ 2024 Plan ”), subject to shareholder approval. The 2024 Plan was approved by the Company’s shareholders at the 2023 Annual General Meeting of Shareholders on October 19, 2023, as further described in

    Read the 8-K filing
14. Jun 26, 2023

    On June 22, 2023, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 11 to 12 and appointed Greg Lewis as a new director of the Company, in each case effective as of June 26, 2023. Mr. Lewis has been appointed to serve on the Audit committee and Finance and Financial Risk committee of the Board. In connection with his appointment to the Board, pursuant to the Company’s non-employee director compensation policy, Mr. Lewis will be eligible to receive an annual cash retainer and a director equity grant, in each case as described under “Corporate Governance—Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on August 19, 2022. There were no arrangements or understandings between Mr.

    Read the 8-K filing
15. Jun 27, 2022

    On June 22, 2022, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 10 to 11 and appointed Lidia L. Fonseca as a new director of the Company, in each case effective as of June 27, 2022. Ms. Fonseca has been appointed to serve on the Science and Technology committee and Compensation committee of the Board. In connection with her appointment to the Board, pursuant to the Company’s non-employee director compensation policy, Ms. Fonseca will be eligible to receive an annual cash retainer and a director equity grant, in each case as described under “Corporate Governance—Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on October 8, 2021. There were no arrangements or understandings between Ms.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.